Advanced in Chronic B-Cell Leukemia (CBCL)

Guy J. Berchem

Luxembourg, LU, LU 
Advanced in Chronic B-Cell Leukemia (CBCL)
Luxembourg, LU, LU 
OverviewLocationsClinical Research

Overview

Guy Berchem practices in Luxembourg, Luxembourg. Mr. Berchem is rated as an Advanced expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Cerebral Hypoxia, Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Lung Cancer.

His clinical research consists of co-authoring 88 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Male

Locations

Luxembourg, LU, Luxembourg
Other Locations
Esch-sur-alzette, ES, Luxembourg
Belvaux, ES L4367, Luxembourg
Strassen, LU, Luxembourg

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Proof of Concept Study to Explore Safety and Efficacy of Tri-therapy Approach in Advanced/Metastatic NSCLC and Retrospectively Assess the Ability of Integrated Genomics and Transcriptomics to Match Patients to the Combination
A Proof of Concept Study to Explore Safety and Efficacy of Tri-therapy Approach in Advanced/Metastatic NSCLC and Retrospectively Assess the Ability of Integrated Genomics and Transcriptomics to Match Patients to the Combination
Enrollment Status: Terminated
Publish Date: December 18, 2023
Intervention Type: Drug
Study Drugs: Avelumab, Axitinib, Palbociclib
Study Phase: Phase 1/Phase 2
Biomarker Discovery and Validation in Lung Cancer
Biomarker Discovery and Validation in Lung Cancer
Enrollment Status: Unknown
Publish Date: February 01, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
View 1 Less Clinical Trial

88 Total Publications

Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model.
Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model.
Journal: Oncoimmunology
Published: April 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Berchem's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile